Related Articles
SERVICES
Core services include processing of hematopoietic stem cells for autologous or allogeneic transplantation, generation of tumor vaccines using genetic or culture mediated modification of tumor…
Second opinion changes course of treatment for marginal zone lymphoma survivor
James Cribbin and his wife, Alexandra, came to MD Anderson for its expertise in marginal zone lymphoma, a rare subtype of non-Hodgkin lymphoma. What they…
Lonsurf and Talzenna for Cancers with TP53 Mutations
The combination of Lonsurf and talazoparib (Talzenna) selectively killed cancer cells with mutations in the TP53 gene, researchers found in a study in mice.
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
Nivolumab monotherapy and nivolumab plus ipilimumab combination therapy showed promise in the CheckMate 358 study as potential treatment options for recurrent or metastatic cervical cancer.…
Interrupting Breast Cancer Endocrine Therapy for Pregnancy : Oncology Times
An abstract is unavailable.
Pembrolizumab Plus Chemo Could Represent New SOC in Advanced/Recurrent Endometrial Cancer
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study
Total national health expenditure is associated with geographical inequalities in lymphoid malignancy prognosis. Policy decisions on allocating economic resources and implementing evidence-based models of care…
CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies
Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.
Cilta-cel May Offer Another Path in Previously Treated Multiple Myeloma
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.